Want to see GB:COG full AI Analyst Report?
Top Page
Cambridge Cognition Holdings
(LSE:COG)
Select Model
Select Model
Rating:44Neutral
Price Target:
32.00 p
▲(3.23% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily held down by weak financial performance, driven by multi-year operating/net losses and ongoing negative free cash flow (despite improvement in 2025). Technicals are mixed with neutral momentum but a generally weaker longer-term trend, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Strong Gross Margins
Consistently high gross margins indicate that the proprietary assessment software and related services have attractive underlying economics. If management can control operating costs and scale study volumes, this margin base could support future operating leverage.
Negative Factors
Persistent Operating Losses
Four consecutive years of operating and net losses show that the current revenue base does not yet cover the company’s operating cost structure. Persistent losses can restrict investment capacity, increase financing dependence, and weaken long-term shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Consistently high gross margins indicate that the proprietary assessment software and related services have attractive underlying economics. If management can control operating costs and scale study volumes, this margin base could support future operating leverage.
Read all positive factors
Cambridge Cognition Holdings (COG) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£16.73M
Dividend YieldN/A
Average Volume (3M)14.48K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth-9.11%
EPS Growth18.91%
CountryUK
Employees74
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding54,037,327
10 Day Avg. Volume17,408
30 Day Avg. Volume14,477
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)4.06
Price to Sales (P/S)1.29
P/FCF Ratio-46.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£11.61M
Cambridge Cognition Holdings Business Overview & Revenue Model
Company Description
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the Un...
How the Company Makes Money
Cambridge Cognition makes money by commercializing its proprietary computerized cognitive tests and associated delivery platforms and services, primarily to pharmaceutical companies, contract research organizations (CROs), and academic/clinical re...
Cambridge Cognition Holdings Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.40M | 10.34M | 13.52M | 12.61M | 10.09M |
| Gross Profit | 7.01M | 8.39M | 10.80M | 9.32M | 8.08M |
| EBITDA | -960.00K | -542.00K | -2.62M | -514.00K | 412.00K |
| Net Income | -1.68M | -1.78M | -3.51M | -409.00K | 450.00K |
Balance Sheet | |||||
| Total Assets | 11.28M | 13.03M | 14.23M | 15.11M | 12.54M |
| Cash, Cash Equivalents and Short-Term Investments | 1.13M | 1.30M | 3.23M | 8.32M | 6.81M |
| Total Debt | 873.00K | 1.91M | 2.56M | 18.00K | 18.00K |
| Total Liabilities | 8.29M | 9.67M | 12.95M | 15.01M | 11.91M |
| Stockholders Equity | 2.99M | 3.36M | 1.28M | 95.00K | 632.00K |
Cash Flow | |||||
| Free Cash Flow | -262.00K | -3.09M | -5.00M | 1.49M | 3.88M |
| Operating Cash Flow | -232.00K | -3.08M | -4.97M | 1.68M | 3.93M |
| Investing Cash Flow | -30.00K | 50.00K | -3.02M | -189.00K | -105.00K |
| Financing Cash Flow | 152.00K | 1.13M | 2.88M | -132.00K | -86.00K |
Cambridge Cognition Holdings Technical Analysis
Negative
31.00
Price Trends
32.42
Negative
33.99
Negative
34.42
Negative
Market Momentum
-0.54
Positive
14.62
Positive
31.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:COG, the sentiment is Negative. The current price of 31 is below the 20-day moving average (MA) of 32.10, below the 50-day MA of 32.42, and below the 200-day MA of 34.42, indicating a bearish trend. The MACD of -0.54 indicates Positive momentum. The RSI at 14.62 is Positive, neither overbought nor oversold. The STOCH value of 31.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:COG.
Cambridge Cognition Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | £67.14M | 24.54 | 8.84% | ― | -5.18% | -66.95% | |
56 Neutral | £16.42M | -3.83 | -16.18% | ― | 13.04% | 15.88% | |
55 Neutral | £124.20M | 1,331.82 | 0.25% | ― | 19.53% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £16.73M | -8.09 | -62.89% | ― | -9.11% | 18.91% | |
42 Neutral | £15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% | |
40 Underperform | £13.01M | -3.75 | -135.35% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:COG
Cambridge Cognition Holdings
31.00
-3.00
-8.82%
GB:IXI
IXICO plc
7.50
-4.35
-36.71%
GB:OBD
Oxford BioDynamics
0.12
-0.37
-76.04%
GB:KOO
Kooth
185.00
33.00
21.71%
GB:DXRX
Diaceutics
146.50
4.50
3.17%
GB:APTA
Aptamer Group Plc
0.38
-0.73
-65.91%
Cambridge Cognition Holdings Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Cambridge Cognition Boosts H1 Revenue, Clears Debt and Funds Expansion Into Digital Brain Health
Positive
Jul 27, 2026
Cambridge Cognition reported a 16% rise in first-half 2026 revenue to £5.0m, including initial sales from its new healthcare and consumer wellness pilots, and has contracted orders indicating at least £10.0m in full-year revenue with six...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Cambridge Cognition Raises £2.6m to Fund Expansion of Digital Neuroscience Platform
Positive
Jul 10, 2026
Cambridge Cognition Holdings plc has secured shareholder approval for a fundraising comprising a placing, subscription and retail offer, raising approximately £2.6 million in gross proceeds. The new shares, totalling 7,407,628, are expected t...
Private Placements and FinancingShareholder Meetings
Cambridge Cognition Raises £2.59m in Conditional AIM Share Issue
Positive
Jun 30, 2026
Cambridge Cognition has closed its retail share offer, raising about £48,000 through the issue of 138,366 shares at 35 pence each, as part of a broader fundraising. Together with an institutional placing and a subscription, the company has co...
Business Operations and StrategyPrivate Placements and Financing
Cambridge Cognition launches retail share offer to fund next growth phase
Positive
Jun 24, 2026
Cambridge Cognition Holdings has launched a UK-only retail offer of new ordinary shares at 35 pence per share via BookBuild, alongside an institutional placing and subscription, as part of a wider equity fundraising. The offer, open to existing UK...
Business Operations and StrategyPrivate Placements and Financing
Cambridge Cognition Raises £2.54m and Plans Retail Offer to Bolster Capital
Positive
Jun 24, 2026
Cambridge Cognition has conditionally raised about £2.54 million before expenses through a placing and subscription of new shares at 35 pence each and plans a further retail offer of up to £0.5 million for existing UK shareholders, with ...
Business Operations and StrategyPrivate Placements and Financing
Cambridge Cognition launches £2.5m equity raise to fund healthcare expansion
Positive
Jun 23, 2026
Cambridge Cognition plans to raise at least £2.5 million through an equity fundraising comprising a placing with institutional investors and a subscription by certain shareholders, directors and senior managers at 35.0 pence per share. The co...
Business Operations and StrategyFinancial Disclosures
Cambridge Cognition to Showcase Growth Momentum and Brain Health Strategy at Mello 2026
Positive
Jun 1, 2026
Cambridge Cognition Holdings will present at the Mello 2026 investor event, where CEO Rob Baker and senior leaders will outline how the company is scaling its brain health technologies, including digital touch-screen and voice-based assessments, f...
Business Operations and Strategy
Cambridge Cognition and Oura team up on large-scale wearable brain health study
Positive
May 28, 2026
Cambridge Cognition has partnered with smart ring maker Oura to launch a large-scale, IRB-approved brain health study that integrates its CANTAB Pathway digital cognitive assessments into the Oura consumer health platform. Up to 45,000 Oura member...
Business Operations and StrategyExecutive/Board ChangesStock BuybackShareholder Meetings
Cambridge Cognition shareholders back all AGM resolutions and board
Positive
May 21, 2026
Cambridge Cognition Holdings reported that all resolutions at its latest annual general meeting were approved by shareholders, with proxy votes representing 59.3% of the company’s issued share capital. Investors backed the 2025 report and ac...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.